<DOC>
	<DOCNO>NCT00981799</DOCNO>
	<brief_summary>Nelarabine show significant activity patient T-cell malignancy . This study determine safety maximum tolerate dose combination nelarabine , cyclophosphamide etoposide patient first bone marrow relapse T-ALL , first relapse T-LL .</brief_summary>
	<brief_title>Trial Nelarabine , Etoposide Cyclophosphamide Relapsed T-cell ALL T-cell LL</brief_title>
	<detailed_description />
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Precursor T-Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<criteria>Patients enrol doseescalation portion study must Tcell ALL Tcell lymphoblastic lymphoma ( LL ) first relapse must fail primary induction chemotherapy ( ie , never attain complete remission follow initial course standard therapy TALL TLL ) . Patients enrol cohort expansion portion study ( ie , treat recommended phase 2 dose ) must Tcell ALL first relapse must fail primary induction chemotherapy ( ie , never attain complete remission follow initial course standard therapy TALL ) . TLL patient eligible cohort expansion phase . Patients Tcell ALL must great 25 % blast bone marrow without extramedullary disease . Patients Tcell LL must recurrent disease , document clinical radiographic criterion , well histologic verification malignancy original diagnosis . Patients Tcell LL enrol phase I doseescalation study require measurable disease ; however , patient enrol phase II cohort expansion MTD must measurable disease . Patients may CNS 1 CNS 2 disease CNS 3 . ECOG 02 Karnofsky ≥ 50 % patient &gt; 16 year age ; Lansky ≥ 50 % patient ≤16 year age . Patients may enrol study regardless time prior Intrathecal therapy ; however , MAY NOT BEGIN TREATMENT ON THIS PROTOCOL UNTIL A MINIMUM OF 7 DAYS HAS ELAPSED SINCE PRIOR INTRATHECAL THERAPY . At least 6 week must elapse since administration nitrosureas . At least 12 week must elapse since administration craniospinal hemipelvic radiation . Female patient childbearing potential must negative urine serum pregnancy test confirm within 2 week prior enrollment . Female patient infant must agree breastfeed infant study . Male female patient childbearing potential must agree use effective method contraception approve investigator study minimum 6 month study treatment . Adequate renal function define serum creatinine ≤ 1.5x upper limit normal ( ULN ) age . If serum creatinine value , calculate creatinine clearance radioisotope GFR must ≥ 70 mL/min/1.73m2 . Total bilirubin ≤ 1.5x ULN age . If total bilirubin elevate , patient still eligible conjugate ( direct ) serum bilirubin ≤ ULN age . ALT ≤ 5x ULN normal age . Adequate cardiac function define shorten fraction ≥ 27 % echocardiogram ejection fraction ≥ 45 % gate radionuclide study . No evidence dyspnea rest No exercise intolerance A pulse oximetry ≥ 94 % sea level ( ≥ 90 % altitude ≥ 5000 foot ) clinical indication determination . Patients and/or parent legal guardian must capable understanding investigational nature , potential risk benefit study . All patient and/or parent legal guardian must sign write informed consent . Patients Down syndrome exclude . Patients preexist Grade 2 ( great ) peripheral motor sensory neurotoxicity per CTCAE 3.0 determine treat physician neurologist . Patients history prior venoocclusive disease ( VOD ) finding consistent diagnosis VOD , define : conjugate serum bilirubin &gt; 1.4 mg/dL AND unexplained weight gain great 10 % baseline weight ascites AND hepatomegaly right upper quadrant pain without another explanation , OR reversal portal vein flow ultrasound , OR pathological confirmation VOD liver biopsy . Previous hematopoetic stem cell transplantation . Patients prior seizure disorder require anticonvulsant therapy eligible receive nelarabine . For purpose study , include patient receive anticonvulsant therapy prevent/treat seizure prior two year . Positive blood culture within 48 hour study enrollment . Fever 38.2 within 48 hour study enrollment clinical sign infection . Plan administer nonprotocol chemotherapy , radiation therapy , immunotherapy study period . Any significant concurrent disease , illness , psychiatric disorder social issue would compromise patient safety compliance , interfere consent , study participation , follow , interpretation study result .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Relapse</keyword>
	<keyword>T cell</keyword>
	<keyword>Lymphoblastic</keyword>
	<keyword>Leukemia</keyword>
	<keyword>Lymphoma</keyword>
	<keyword>Nelarabine</keyword>
	<keyword>TACL</keyword>
	<keyword>NECTAR</keyword>
</DOC>